171046-47-2

Upstream product

• 143168-16-5 ethyl (R)-5-acetoxycyclopent-1-enecarboxylate 
• 824-98-6 m-methoxybenzyl chloride 

Downstream Products

• 911676-51-2 3-[(1S,2S)-2-(4,5-Diphenyl-oxazol-2-yl)-cyclopentylmethyl]-phenol 
• 911676-52-3 3-[(1S,2R)-2-(4,5-Diphenyl-oxazol-2-yl)-cyclopentylmethyl]-phenol 
• 911676-49-8 2-[(1S,2S)-2-(3-Methoxy-benzyl)-cyclopentyl]-4,5-diphenyl-oxazole 
• 911676-50-1 2-[(1R,2S)-2-(3-Methoxy-benzyl)-cyclopentyl]-4,5-diphenyl-oxazole 
• 171046-58-5 (+)-(5S)-1-(4,5-diphenyloxazol-2-yl)-5-(3-methoxybenzyl)cyclopentene 
• 171046-88-1 (S)-5-(3-Methoxy-benzyl)-cyclopent-1-enecarbonyl chloride 
• 171046-49-4 (-)-5(S)-(3-methoxybenzyl)-1-cyclopentenecarboxylic acid 

Relevant academic research and scientific papers

Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: Orally active prostacyclin mimetics. Part 6

The synthesis and biological activity of novel derivatives of our previously reported IP receptor agonist FR181157 is described. SAR studies to replace the cyclohexene-linker of FR181157 led to the discovery of compound 1i (FR207845) as a potent non-prost

4,5-diaryloxazole derivatives

Heterocyclic compounds of the formula: whereinR1 is carboxy or protected carboxy, R2 is aryl which may have suitable substituent(s), R3 is aryl which may have suitable substituent(s), A1 is lower alkylene, A2 is bond or lower alkylene and -Q- is etc., and pharmaceutically acceptable salts thereof which are useful as a medicament.